

Department of Vermont Health Access Pharmacy Benefits Management Program DUR Board Meeting Agenda

April 6, 2021: 6:30 – 8:30 p.m.

11pm 6, 2021. 0.30 0.30 p.m.		
•	Executive Session	6:00 - 6:30
•	Introductions and Approval of DUR Board Minutes (Public Comment Prior to Board Action)	6:30 - 6:35
•	DVHA Pharmacy Administration Updates	6:40 - 6:45
•	Medical Director Update	6:45 - 6:50
•	Follow-up Items from Previous Meetings Cumulative Morphine Milligram Equivalent (MME)	6:50 – 7:00
•	RetroDUR/ProDUR Introduce: Influenza Vaccination Rates Data presentation: Sublocade Adherence	7:00- 7:25
•	Clinical Update: Drug Reviews (Public comment prior to Board action)	7:25-7:55

Biosimilar Drug Reviews

None at this time

Full New Drug Reviews

(Any new drug reviews that also fall within the Therapeutic Class Review (TCR) will be discussed during the Therapeutic Class Review)

- Armonair Digihaler® (fluticasone propionate) and Airduo Digihaler® (fluticasone propionate and salmeterol)
- Alkindi® (hydrocortisone oral granules) and Hemady® (dexamethasone)
- Fintepla® (fenfluramine)
- Ongentys® (opicapone)
- Phexxi® Gel (Lactic Acid, Ctric Acid, and Potassium Bitartrate Vaginal Gel)
- Twirla® (levonorgestrel & ethinyl estradiol)
- Xywav® (calcium, magnesium, potassium, and sodium oxybates oral solution)

New Managed Therapeutic Drug Classes

7:55 -7:55

(Public comment prior to Board action)

None at this time

Therapeutic Drug Classes – Periodic Review

7:55 - 8:30

	Hepatitis C TreatmentsLipotropics, Other (Non-Statins)Lipotropics, Statins	
•	Review of Newly Developed/Revised Criteria (Public comment prior to Board action) None at this time.	8:30 - 8:30
•	General Announcements	8:30 - 8:30
	Adjourn	8:30

Angiotensin Modulators and Heart Failure Agents Beta-Blockers, Anti-Anginal, and Sinus Node Agents

• Anti-Migraine Agents, Triptans & CGRP Antagonists

(Public comment prior to Board action)

Calcium Channel Blockers

Bile Salt Agents Botulinum Toxins